Trials / Completed
CompletedNCT04365127
Progesterone for the Treatment of COVID-19 in Hospitalized Men
A Single Center, Randomized, Controlled Trial of the Safety and Efficacy of Progesterone for the Treatment of COVID-19 in Hospitalized Men
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Sara Ghandehari · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess safety and efficacy of progesterone for treatment of COVID-19 in hospitalized men.
Detailed description
Hospitalized men with COVID-19 who meet the eligibility criteria will be informed about study and the potential risks. All the patients giving written informed consent will be randomized in 1:1 ratio to progesterone (100 mg SQ twice daily) plus standard of care or standard of care alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Progesterone 100 MG | Subcutaneous administration twice daily |
Timeline
- Start date
- 2020-04-27
- Primary completion
- 2020-08-20
- Completion
- 2020-08-20
- First posted
- 2020-04-28
- Last updated
- 2021-01-27
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04365127. Inclusion in this directory is not an endorsement.